CDA Formulations as Superb and Excellent Cancer Drugs to Save Cancer Patients
Author(s):
Ming C Liau*, Christine L Craig and Linda L Baker
The objective of this article is to develop effective cancer drugs to save cancer patients. There are three categories of cancer drugs: the superb cancer drugs are those that can prevent cancer from taking place, the excellent cancer drugs are those to target on the causes of cancer, and ordinary cancer drugs are those to focus on the elimination of symptoms. Cancer therapy had a bad to rely on toxic chemicals to kill cancer cells (CCs), the most outstanding symptom of cancer, which was a mistake committed at a time we did not have a complete knowledge of cancer. Cytotoxic agents were the choice of cancer establishment to combat cancer when President Nixon declared war on cancer during 1971-1976, which was not successful. Despite failure, cytotoxic agents continued to dominate cancer therapy because cancer establishments could not find drugs better than failed cytotoxic agents to kill CCs. The consequence is as expected that cancer mortality keeps on escalating. Cancer stem cells (CSCs) became known in 1997. The discovery of CSCs unraveled an important issue of cancer. It became evident that, although CSCs constituted only a small sub-population, these cells were responsible for the initiation of tumor growth and the treatment failure. Therefore, the elimination of CSCs is essential to the success of cancer therapy. Our studies of abnormal methylation enzymes (MEs), chemo-surveillance, and wound healing were closely related to the issue of CSCs. Thus, we are in a unique position to offer the best solution of CSCs to save cancer patients.
Wound healing is an important health issue. The nature creates chemo-surveillance to ensure perfection of wound healing to avoid disastrous consequences of wound unhealing, cancer being the worst. Chemo-surveillance is specifically destroyed in cancer patients to result in wound unhealing, which forces progenitor stem cells (PSCs) to evolve into cancer stem cells (CSCs), and then to progress to faster growing CCs. PSCs are the most primitive stem cells to initiate the development of organ or tissue during embryonic development of the fetus. These cells are also the cells involved in wound healing. MEs of PSCs are abnormal due to association with telomerase, which are an important cause of cancer to promote perpetual proliferation by blocking differentiation. Chemo-surveillance is the nature’s creation of allosteric regulation on abnormal MEs to prevent the buildup of cells with abnormal MEs to become clinical problems. Human body produces metabolites active as differentiation inducers (DIs) and differentiation helper inducers (DHIs), which are wound healing metabolites and also the active components of chemo-surveillance. Protection of the functionality of chemo-surveillance is important to ensure perfection of wound healing to avoid cancer. Pathological conditions inducing the production of tumor necrosis factor (TNF) are particularly damaging to chemosurveillance. Anti-cachexia chemical phenylacetylglutamine can effectively antagonize the effect of TNF to protect chemo-surveillance. Phenylacetylglutamine is, therefore, a superb cancer drug that can prevent cancer from taking place.
Cell differentiation agent-2 (CDA-2) is a preparation of wound healing metabolites purified from urine, which has been approved by the Chinese FDA for the therapy of cancer and myelodysplastic syndromes (MDSs). MDSs are diseases attributable entirely to CSCs. CDA-2 is demonstrably the best drug for the therapy of MDSs, showing superior therapeutic efficacy without adverse effects. Phenylacetylglutamine is a major chemical component, and DIs and DHIs are the active anti-cancer components effective to destabilize abnormal MEs and to eliminate CSCs, both of which are critical causes of cancer. CDA-2 fit the description as superb and excellent cancer drugs. We have carried extensive studies on natural and non-natural DIs and DHIs to manufacture CDA formulations. Cancer establishments stand in the way to block the development of CDA formulations, which is a difficult hurdle.
